Provident Investment Management Inc. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 70.4% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 10,097 shares of the company’s stock after acquiring an additional 4,173 shares during the period. Provident Investment Management Inc.’s holdings in Johnson & Johnson were worth $1,225,000 at the end of the most recent reporting period.
Several other institutional investors also recently added to or reduced their stakes in the stock. Financial Gravity Wealth Inc. acquired a new position in Johnson & Johnson during the first quarter worth $105,000. WP Advisors LLC acquired a new position in Johnson & Johnson during the second quarter worth $108,000. FNY Investment Advisers LLC acquired a new position in Johnson & Johnson during the second quarter worth $117,000. Fusion Family Wealth LLC raised its holdings in Johnson & Johnson by 621.4% during the second quarter. Fusion Family Wealth LLC now owns 1,010 shares of the company’s stock worth $123,000 after buying an additional 870 shares during the last quarter. Finally, Live Your Vision LLC raised its holdings in Johnson & Johnson by 58.3% during the second quarter. Live Your Vision LLC now owns 1,363 shares of the company’s stock worth $172,000 after buying an additional 502 shares during the last quarter. Institutional investors own 66.51% of the company’s stock.
Several analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $164.00 target price for the company in a research note on Wednesday. Wells Fargo & Co reiterated an “outperform” rating and issued a $160.00 target price (up previously from $155.00) on shares of Johnson & Johnson in a research note on Wednesday, October 17th. HC Wainwright reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Wednesday, October 17th. Raymond James upped their target price on shares of Johnson & Johnson from $144.00 to $149.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 17th. Finally, Credit Suisse Group set a $149.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Sunday, October 14th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $143.90.
NYSE JNJ opened at $146.03 on Thursday. The firm has a market capitalization of $391.78 billion, a PE ratio of 20.00, a PEG ratio of 2.28 and a beta of 0.59. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.72 and a quick ratio of 1.40. Johnson & Johnson has a 1 year low of $118.62 and a 1 year high of $148.99.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.03 by $0.02. The company had revenue of $20.35 billion during the quarter, compared to analyst estimates of $20.05 billion. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The firm’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.90 earnings per share. Analysts forecast that Johnson & Johnson will post 8.16 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 11th. Investors of record on Tuesday, November 27th will be given a dividend of $0.90 per share. The ex-dividend date is Monday, November 26th. This represents a $3.60 annualized dividend and a yield of 2.47%. Johnson & Johnson’s payout ratio is currently 49.32%.
In related news, EVP Michael E. Sneed sold 30,943 shares of the stock in a transaction dated Friday, November 23rd. The shares were sold at an average price of $142.46, for a total transaction of $4,408,139.78. Following the completion of the transaction, the executive vice president now owns 70,817 shares in the company, valued at $10,088,589.82. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CAO Ronald A. Kapusta sold 8,441 shares of the stock in a transaction dated Thursday, November 8th. The shares were sold at an average price of $145.15, for a total transaction of $1,225,211.15. Following the transaction, the chief accounting officer now owns 17,284 shares of the company’s stock, valued at approximately $2,508,772.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 351,748 shares of company stock valued at $51,092,647. 0.22% of the stock is owned by company insiders.
COPYRIGHT VIOLATION WARNING: “Provident Investment Management Inc. Grows Position in Johnson & Johnson (JNJ)” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/12/06/provident-investment-management-inc-grows-position-in-johnson-johnson-jnj.html.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: Bear Market
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.